癌治療ワクチンの世界市場

VacZine Analyticsが発行した調査報告書(VACZ712002)
◆英語タイトル:MarketVIEW: Therapeutic cancer vaccines
◆商品コード:VACZ712002
◆発行会社(リサーチ会社):VacZine Analytics
◆発行日:2017年2月
◆ページ数:※お問い合わせください。
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD5,780 ⇒換算¥653,140見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はVacZine Analytics社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。VacZine Analytics社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Cancer is one of the leading causes of death worldwide causing approximately 1 in every 7 deaths. In 2012, 8.2 million people died of the disease with 14 million new cases recorded in that year (WHO Figures). In 2030, the number of new cancer cases is projected to be >22 million (50-70% increase) due to the increasing population age and size.
Cancer immunotherapy (active and passive) aims to harness the body’s own immune system in the fight against tumour progression. In the past decade, this strategy has become the most promising in the search for novel cancer therapies. Recent breakthroughs include either tumour specific/bi-specific monoclonal antibodies (mAbs), checkpoint inhibitors, adoptive cell therapy and therapeutic cancer vaccines (peptides, dendritic cells, allogenic cells, autologous cells, oncolytic viruses). For the latter group, Dendreon’s Provenge® (Sipuleucel-T) was the first therapeutic vaccine approved for any cancer.

This MarketVIEW product consists of a detailed Executive presentation (~100 slides) and MS-Excel work book summarizing current approaches in cancer immunotherapy with an in-depth focus on the therapeutic cancer vaccine category. Included is an analysis of over 300 verified cancer vaccine programs (Phase I-III) delineated by sponsor, sponsor type, mechanism, tumour type, results, and other relevant fields. Detailed case studies are presented for the identified late stage (Phase III) industry sponsored programs e.g. PROSTVAC® Bavarian Nordic with presentation of clinical trial data relevant to the Provenge® (Sipuleucel-T) reference for FDA approval. This analysis is recommended to any client wishing to understand quickly the commercial landscape of the therapeutic cancer vaccine field within the overview dynamic of cancer immunotherapy.

THIS PRODUCT IS A SUMMARY PRESENTATION + ONE WORKBOOK

【レポートの目次】

Contents
Executive summary
Cancer and immunotherapy
Cancer immunotherapy: broad approaches
Overview
Introduction to cancer vaccines
Types of cancer vaccines
Cancer vaccine approaches: cell-based vaccines
Cancer vaccine approaches: peptide-based vaccines
Cancer vaccine approaches: DNA vaccines
Cancer vaccine approaches: RNA vaccines
Cancer vaccine approaches: Viral vector vaccines
Cancer vaccine approaches: Oncolytic viruses
Approved therapeutic cancer vaccines
Provenge® (Sipuleucel-T)
Provenge® (Sipuleucel-T): Phase III data
Provenge® (Sipuleucel-T): Ongoing trials
Current R&D pipeline
Cancer vaccines: pipeline analysis methodology
Cancer vaccine trials (Phase I-III), by tumour type
Cancer vaccine trials, by phase and sponsor type 2016
Cancer vaccine trials, by tumour and sponsor type 2016
Cancer vaccine trial phases verified 2016 per tumour tissue
Cancer vaccine phase III trials per tumour type
Cancer vaccine trials conducted for single vs multiple tissue tumours – verified in 2016
Industry sponsored Phase II/III and Phase III cancer vaccine trials verified in 2016
Melanoma
Seviprotimut-L (POL-103A) – Polynoma
Seviprotimut-L (POL-103A): Phase II data
Prostate Cancer
PROSTVAC® (rilimogene galvacirepvac) – Bavarian Nordic
PROSTVAC® : Phase II data
PROSTVAC® : Phase III trial (ongoing)
PROSTVAC® : Key ongoing trials
ProstAtak® (AdV-tk) – Advantagene Inc
ProstAtak® (AdV-tk) – Phase II trial
DCVAC/PCa – Sotio

DCVAC/PCa: Phase II data
DCVAC/PCa: Key ongoing trials
Brain Cancer
DCVax®-L - Northwest Biotherapeutics
DCVax®-L: Phase I/II DCVax-L Trials
DCVax®-L: Key ongoing trials
ICT-107 - Immunocellular Therapeutics Ltd
ICT-107: Phase II data
Ovarian Cancer
Vigil® (gemogenovatucel-T, FANGTM) - Gradalis
Vigil®: Phase II data
Vigil®: Key ongoing trials
Colon Cancer
ALLOSTIM® - Immunovative Therapies Ltd
ALLOSTIM®: Phase I/II data
ALLOSTIM®/ Allovax®: Key ongoing trials
Lung Cancer
Tedopi® (OSE2101) - OSE Immunotherapeutics
Tedopi® (OSE-2101, IDM-2101)): Phase II data
Vaxira® (Racotumomab-alum, 1E10) - Recombio
Vaxira® (Racotumomab-alum, 1E10): Phase II data
EGF PTI (BV-NSCLC-002) - Bioven
EGF PTI (BV-NSCLC-002): Phase II data
HyperAcuteTM (Tergenpumatucel-L) - NewLink Genetics Corporation
HyperAcuteTM (Tergenpumatucel-L): Phase II study
Appendix: Historical analysis since 1991
Cancer vaccine trials to date: Historical view since 1991
Cancer vaccine trials to date - Result status historical view
Cancer Vaccine Trials to Date - Trial phase historical view
Cancer Vaccine Trials to Date - Trials conducted for single vs multiple tissue tumours - historical view
Cancer vaccine trials - Last verification dates
Cancer vaccine trials - Last verification dates 2001-2016 by tissue
Cancer vaccines: development history summary
Slide number = 99

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 癌治療ワクチンの世界市場(MarketVIEW: Therapeutic cancer vaccines)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆